Harmony Biosciences Holdings, Inc.
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
HRMY$33.55-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
STATEMENTS OF STOCKHOLDERS’ EQUITY
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · Accumulated · · · · · | |||||||||||||||||
| · · · · · · · Additional · · other · · · · · Total | |||||||||||||||||
| · · Common Stock · · paid-in · · comprehensive · · Retained · · stockholders’ | |||||||||||||||||
| · Shares · Amount · capital · income · earnings · equity | |||||||||||||||||
| Balance as of December 31, 2024 | 57,144,887 | | $1 | | $656,872 | | $66 | | $2,216 | | $659,155 | ||||||
| Net income | — | | — | | — | | | — | | 45,560 | | 45,560 | |||||
| Unrealized gain on investments | | — | | | — | | | — | | | 179 | | | — | | | 179 |
| Exercise of options and restricted stock units | 248,786 | | — | | 3,132 | | | — | | — | | 3,132 | |||||
| Stock-based compensation | — | | — | | 12,499 | | | — | | — | | 12,499 | |||||
| Balance as of March 31, 2025 | 57,393,673 | | $1 | | $672,503 | | $245 | | $47,776 | | $720,525 | ||||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · Accumulated · · | |||||||||||||||||
| · · · · · · · Additional · · other · · · · Total | |||||||||||||||||
| · · Common Stock · · paid-in · · comprehensive · · Accumulated · · stockholders’ | |||||||||||||||||
| · Shares · Amount · capital · · (loss) income · deficit · equity | |||||||||||||||||
| Balance as of December 31, 2023 | 56,769,081 | | $1 | | $610,266 | | $2 | | $(143,277) | | $466,992 | ||||||
| Net income | — | | — | | — | | | — | | 38,334 | | 38,334 | |||||
| Unrealized loss on investments | | — | | | — | | | — | | | (173) | | | — | | | (173) |
| Exercise of stock options and restricted stock units | 22,133 | | — | | (153) | | | — | | — | | (153) | |||||
| Stock-based compensation | — | | — | | 10,394 | | | — | | — | | 10,394 | |||||
| Balance as of March 31, 2024 | 56,791,214 | | $1 | | $620,507 | | $(171) | | $(104,943) | | $515,394 | ||||||
The* *accompanying notes are an integral part of the unaudited condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.